New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting

Reductions in annualized relapse rates shown in pivotal trials with ozanimod were consistent in subgroups including baseline disability gadoliniumenhanced lesion status and prior exposure to diseasemodifying therapies versus interfe...